Metabolic control in patients with schizophrenia treated with amisulpride or olanzapine.

abstract：:This retrospective cohort study was performed to investigate the association between risperidone and deteriorating performance in walking and dressing in subjects with Parkinson's disease using the Japanese Diagnosis Procedure Combination data. These data include inpatient claims including information from the time of...

journal_title：International clinical psychopharmacology

authors： Iketani R,Imai S,Horiguchi H,Furushima D,Fushimi K,Yamada H

更新日期：2019-09-01 00:00:00

abstract：:Recent studies have shown that the use of subscales derived from the Hamilton Depression (HAM-D) rating scale are just as reliable and enhance sensitivity for detecting response and remission after antidepressant treatment. The purpose of the present study was to determine if the responses on two items of the HAM-D sc...

journal_title：International clinical psychopharmacology

authors： Silverstone PH,Entsuah R,Hackett D

更新日期：2002-11-01 00:00:00

abstract：:The 6-month prevalence of depression in the Italian community was evaluated by means of the modified-Mini-International-Neuropsychiatric Interview (MINI) administered with a computer-prompted interview to a representative panel of 3550 individuals. Major depression and minor depression accounted for 8.0% and 2.9% of t...

journal_title：International clinical psychopharmacology

authors： Dubini A,Mannheimer R,Pancheri P

更新日期：2001-01-01 00:00:00

abstract：:The therapeutic concentrations of antipsychotic drugs in the patient's plasma water or spinal fluid are identical to their blocking potencies in vitro at the dopamine D2 receptor, with the exception of clozapine which acts at D4. The variation in K values between laboratories stems from the fact that the apparent K va...

journal_title：International clinical psychopharmacology

authors： Seeman P

更新日期：1995-09-01 00:00:00

abstract：:The clock-drawing test (CDT) is used widely to evaluate cognitive disorders, but its role in the assessment of psychotic disorders has not been studied. We sought to examine whether the CDT plays a role as an indicator of psychosis and to establish its sensitivity to clinical improvement of psychosis. The CDT was admi...

journal_title：International clinical psychopharmacology

authors： Tene O,Sigler M,Shiloh R,Weizman A,Aizenberg D

更新日期：2016-05-01 00:00:00

abstract：:In a randomized prospective clinical trial with an observation period of 2.5 years, a subgroup analysis was carried out for the 114 patients with bipolar I disorder (DSM-IV) regarding the prophylactic efficacy of lithium and carbamazepine. Treatment outcome was evaluated taking rehospitalization, recurrence, subclinic...

journal_title：International clinical psychopharmacology

authors： Greil W,Kleindienst N

更新日期：1999-09-01 00:00:00

abstract：:Clinical trials are becoming increasingly international in scope. Global studies pose unique challenges in training and calibrating raters owing to language and cultural differences. Recent findings that poorly conducted interviews reduce study power, makes attention to raters' clinical skills critical. In this study,...

journal_title：International clinical psychopharmacology

authors： Jeglic E,Kobak KA,Engelhardt N,Williams JB,Lipsitz JD,Salvucci D,Bryson H,Bellew K

更新日期：2007-07-01 00:00:00

abstract：:A total of 101 patients entered a double-blind, parallel-group study in general practice, comparing the efficacy and tolerability of paroxetine and amitriptyline in elderly depressed patients. All patients received placebo for 1 week followed by active therapy for a total of 6 weeks. Medication was randomly allocated,...

journal_title：International clinical psychopharmacology

authors： Hutchinson DR,Tong S,Moon CA,Vince M,Clarke A

更新日期：1992-06-01 00:00:00

abstract：:Levomilnacipran (1S, 2R-milnacipran) is a potent and selective serotonin and norepinephrine reuptake inhibitor that is Food and Drug Administration approved for once-daily treatment of major depressive disorder in adults. Secondary and post-hoc analyses were carried out on data from a positive 10-week, randomized, dou...

journal_title：International clinical psychopharmacology

authors： Montgomery SA,Mansuy L,Ruth AC,Li D,Gommoll C

更新日期：2014-01-01 00:00:00

abstract：:The pattern of brain metabolic changes produced by olanzapine has yet to be described, despite the theoretical and clinical interest of this new antipsychotic. We studied a group of 17 schizophrenic patients who underwent two fluoro-deoxyglucose-positron emission tomography (FDG-PET) studies under two different condit...

journal_title：International clinical psychopharmacology

authors： Molina V,Gispert JD,Reig S,Pascau J,Martínez R,Sanz J,Palomo T,Desco M

更新日期：2005-01-01 00:00:00

abstract：:Quetiapine ('Seroquel') is a well-tolerated, novel, atypical antipsychotic with consistent efficacy in the treatment of schizophrenia. To date, no clinical studies have evaluated the effect of quetiapine in patients who only partially respond to conventional antipsychotics, yet this type of patient is most frequently ...

journal_title：International clinical psychopharmacology

authors： Emsley RA,Raniwalla J,Bailey PJ,Jones AM

更新日期：2000-05-01 00:00:00

abstract：:Nocturnal eating/drinking syndrome secondary to neuroleptic-induced restless legs syndrome (RLS) occurred under treatment with low-dose haloperidol in a 51-year-old female schizophrenic patient. Polysomnographic investigation showed a low level of sleep efficacy, periodic leg movements, and a strict relationship betwe...

journal_title：International clinical psychopharmacology

authors： Horiguchi J,Yamashita H,Mizuno S,Kuramoto Y,Kagaya A,Yamawaki S,Inami Y

更新日期：1999-01-01 00:00:00

abstract：:The objective of this study was to assess the response of anxiety and depression symptoms to methylphenidate (MPH) treatment in patients with Asperger syndrome (AS) combined with attention deficit/hyperactivity disorder (ADHD). A group of 12 patients with AS/ADHD, aged 8-18 years, received 12 weeks of MPH treatment. T...

journal_title：International clinical psychopharmacology

authors： Golubchik P,Rapaport M,Weizman A

更新日期：2017-09-01 00:00:00

abstract：:Body dysmorphic disorder (BDD) is a relatively common and impairing disorder. Selective serotonin reuptake inhibitors (SRIs) appear selectively efficacious for BDD, but pharmacotherapy research is limited, and escitalopram has not been studied. Fifteen subjects with BDD were treated with escitalopram and assessed with...

journal_title：International clinical psychopharmacology

authors： Phillips KA

更新日期：2006-05-01 00:00:00

abstract：:Sparse data exist regarding the risks and benefits of treating bipolar-II depression with antidepressants alone. On the basis of studies of bipolar-I patients, treatment guidelines suggest antidepressants should be augmented with mood stabilizers. Whether these recommendations apply to bipolar-II is unclear. A post-ho...

journal_title：International clinical psychopharmacology

authors： Agosti V,Stewart JW

更新日期：2007-09-01 00:00:00

abstract：:The treatment of depressed patients with a fixed dose of amitriptyline is compared to treatment with an individualized dose calculated by means of a simple pharmacokinetic test. Clinical response and the development of side-effects are compared between the two groups of patients. Although the numbers in the groups wer...

journal_title：International clinical psychopharmacology

authors： Roy D,Dawling S

更新日期：1987-10-01 00:00:00

abstract：:Although life prevalence of substance use disorders among patients with schizophrenia is close to 50%, few studies have been carried out to date to identify an integrated pharmacological treatment for this comorbidity. So far, the most promising results, that we report here, have been obtained with clozapine. To a les...

journal_title：International clinical psychopharmacology

authors： Potvin S,Stip E,Roy JY

更新日期：2003-05-01 00:00:00

abstract：:The prevalence of tardive dyskinesia in a consecutive series of 69 patients with bipolar affective disorder admitted to a catchment area service was found to be 19%. Prevalence increased with age and was related to the age of onset of bipolar disorder and number of previous episodes. Patients with tardive dyskinesia w...

journal_title：International clinical psychopharmacology

authors： Hunt N,Silverstone T

更新日期：1991-04-01 00:00:00

abstract：:Panic disorder has recently been recognized as a distinct sub-type of anxiety which may occur with or without phobic avoidance. Controlled prospective trials have demonstrated the efficacy of the tricyclic antidepressants and monoamine oxidase inhibitors in the treatment of this disorder. The use of benzodiazepines an...

journal_title：International clinical psychopharmacology

authors： Judd FK,Norman TR,Burrows GD

更新日期：1986-01-01 00:00:00

abstract：:Social phobia was neglected by psychopharmacologically oriented researchers until the past decade. Benefitting from the experience with other anxiety and other affective disorders, however, and also from unique interdisciplinary collaborative arrangements between psychopharmacological and cognitive behavioral investig...

journal_title：International clinical psychopharmacology

authors： Liebowitz MR,Heimberg RG

更新日期：1996-06-01 00:00:00

abstract：:The tendency of antipsychotics to produce extrapyramidal side-effects varies inversely with their antimuscarinic activity. This paper reviews the antipsychotic and antimuscarinic potency of these drugs and compares the total antimuscarinic activity in standard daily doses of antipsychotics, antiparkinson agents and an...

journal_title：International clinical psychopharmacology

authors： Menkes DB,Clarkson HO,Caradoc-Davies G,Mullen PE

更新日期：1987-01-01 00:00:00

abstract：:Good evidence now exists for a therapeutic action of carbamazepine (CBZ) both in acute mania and in the prophylaxis of manic depression. Comparison with other existing therapies and incidence of adverse effects in psychiatric patients also deserve more clinical research. This paper reviews these clinical issues and th...

journal_title：International clinical psychopharmacology

authors： Elphick M

更新日期：1988-07-01 00:00:00

abstract：:Duloxetine, an inhibitor of serotonin and norepinephrine reuptake, has been approved for the treatment of major depressive disorder. In this analysis, data from eight, double-blind, placebo-controlled duloxetine trials were pooled, and the response to duloxetine treatment (40-120 mg/day) was compared between patients ...

journal_title：International clinical psychopharmacology

authors： Perahia DG,Kajdasz DK,Royer MG,Walker DJ,Raskin J

更新日期：2006-09-01 00:00:00

abstract：:In a double-blind multi-centre study of general practice patients with DSM-III-R major depressive disorder, sertraline (50 or 100 mg/day) was compared with dothiepin (75 or 150 mg/day) and with placebo. There were 83, 96 and 90 patients evaluated in the respective treatment groups; treatment lasted 6 weeks. Patients w...

journal_title：International clinical psychopharmacology

authors： Doogan DP,Langdon CJ

更新日期：1994-07-01 00:00:00

abstract：:On the basis of numerous previous studies, the serotonergic system plays a role in the pathogenesis of obsessive-compulsive disorder (OCD) and effective agents in this pathway, such as 5-hydroxytryptophan, can potentially contribute to treatment of patients with this disorder. Evaluating the efficacy of 5-hydroxytrypt...

journal_title：International clinical psychopharmacology

authors： Yousefzadeh F,Sahebolzamani E,Sadri A,Mortezaei A,Aqamolaei A,Mortazavi SH,Shalbafan MR,Ghaffari S,Alikhani R,Mousavi SB,Naderi S,Shamabadi A,Jalilevand S,Akhondzadeh S

更新日期：2020-09-01 00:00:00

abstract：:We compared the antidepressant efficacy and patient tolerance of two different doses of milnacipran (75 mg and 150 mg daily) in 66 outpatients with major depression, using the 17-item Hamilton Depression Rating Scale (HDRS). Only new patients who had never experienced frank depressive episodes before, or those who had...

journal_title：International clinical psychopharmacology

authors： Kanemoto K,Matsubara M,Yamashita K,Tarao Y,Inada E,Sekine T

更新日期：2004-11-01 00:00:00

abstract：:In a double-blind, between-patient clinical trial carbamazepine (CBZ) (n = 8) was compared to haloperidol (HP) (n = 9) in patients presenting with mania (DSM III). Seven patients on HP and 2 on CBZ failed to complete 4 weeks treatment. In 4 of the HP group this was because of extrapyramidal side-effects (EPS). Two pat...

journal_title：International clinical psychopharmacology

authors： Brown D,Silverstone T,Cookson J

更新日期：1989-07-01 00:00:00

abstract：:Most depressive disorders can be viewed as recurrent conditions that may reduce quality of life and productivity. Results of controlled clinical trials indicate that patients should receive 4-6 months of continuation therapy after remission of the acute phase of the illness. Patients at risk of recurrent episodes, how...

journal_title：International clinical psychopharmacology

authors： Kasper S

更新日期：1993-01-01 00:00:00

abstract：:Recent evidence has demonstrated the efficacy of pegylated interferon-alpha (IFN-alpha) in treating hepatitis C virus infection. Neuropsychiatric complications commonly occur during the course of IFN treatment, with depressive symptoms usually appearing within the first 12 weeks. Few cases of the pegylated interferon-...

journal_title：International clinical psychopharmacology

authors： Sockalingam S,Balderson K

更新日期：2005-09-01 00:00:00

abstract：:Social dysfunction is often associated with depressive disorders and its evaluation is an important measure of treatment outcome. The aim of this study was to assess the effect of two treatments, venlafaxine and amitriptyline, on the social functioning of depressed patients. Twenty-eight outpatients, meeting criteria ...

journal_title：International clinical psychopharmacology

authors： Gorenstein C,Andrade L,Moreno RA,Artes R

更新日期：2002-07-01 00:00:00